{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:38:40Z","timestamp":1793140720966,"version":"4.5.0"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordination of Higher Education Personnel Improvement","doi-asserted-by":"publisher","award":["848\/15"],"award-info":[{"award-number":["848\/15"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["420086\/2023\\u20134"],"award-info":[{"award-number":["420086\/2023\\u20134"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2023\/16182-2"],"award-info":[{"award-number":["2023\/16182-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.pnpbp.2025.111456","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T15:32:51Z","timestamp":1752852771000},"page":"111456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems"],"prefix":"10.1016","volume":"141","author":[{"given":"Glauce Crivelaro","family":"Nascimento","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Gon\u00e7alves","family":"B\u00e1lico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Andretto","family":"de Mattos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Dos-Santos-Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Gustavo Carvalho","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eug\u00eania Costa","family":"Queiroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"do Carmo Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Carlos","family":"Navegantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Silveira","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Del-Bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Pt 3","key":"10.1016\/j.pnpbp.2025.111456_bb0005","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.neubiorev.2014.03.026","article-title":"Modulation of defensive behavior by transient receptor potential Vanilloid Type-1 (TRPV1) channels","volume":"46","author":"Aguiar","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111456_bb0010","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/nbdi.1999.0259","article-title":"Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson\u2019s disease","volume":"6","author":"Andersson","year":"1999","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0015","article-title":"Rating L-DOPA-induced Dyskinesias in the unilaterally 6-OHDA-lesioned rat model of Parkinson\u2019s disease","volume":"176","author":"Bariotto-Dos-Santos","year":"2021","journal-title":"J. Visualiz. Exp.\u202f: JoVE"},{"key":"10.1016\/j.pnpbp.2025.111456_bb0020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bbr.2015.07.019","article-title":"The endocannabinoid, endovanilloid and nitrergic systems could interact in the rat dorsolateral periaqueductal gray matter to control anxiety-like behaviors","volume":"293","author":"Batista","year":"2015","journal-title":"Behav. Brain Res."},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111456_bb0025","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.989717","article-title":"Cannabidiol for neurodegenerative disorders: A comprehensive review","volume":"13","author":"Bhunia","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.pnpbp.2025.111456_bb0035","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/mds.27900","article-title":"Neuroinflammation: fanning the fire of l-dopa-induced dyskinesia","volume":"34","author":"Bishop","year":"2019","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111456_bb0040","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of AEA","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0045","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.nbd.2014.10.017","article-title":"Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson\u2019s disease","volume":"73","author":"Bortolanza","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"1672","key":"10.1016\/j.pnpbp.2025.111456_bb0050","first-page":"20140190","article-title":"Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson\u2019s disease induced by L-DOPA?","volume":"370","author":"Bortolanza","year":"2015","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111456_bb0055","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12640-016-9618-4","article-title":"Antidyskinetic effect of 7-Nitroindazole and sodium nitroprusside associated with amantadine in a rat model of Parkinson\u2019s disease","volume":"30","author":"Bortolanza","year":"2016","journal-title":"Neurotox. Res."},{"issue":"13","key":"10.1016\/j.pnpbp.2025.111456_bb0060","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1111\/bph.15439","article-title":"Doxycycline and its derivative, COL-3, decrease dyskinesia induced by l-DOPA in hemiparkinsonian rats","volume":"178","author":"Bortolanza","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111456_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158779","article-title":"Fluorinated Cannabidiol derivatives: enhancement of activity in mice models predictive of anxiolytic, antidepressant and antipsychotic effects","volume":"11","author":"Breuer","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111456_bb0070","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.pnpbp.2009.08.017","article-title":"Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids","volume":"33","author":"Campos","year":"2009","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111456_bb0075","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1017\/S1461145712001502","article-title":"The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system","volume":"16","author":"Campos","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111456_bb0080","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/brainsci14050514","article-title":"Neuroinflammation and dyskinesia: A possible causative relationship?","volume":"14","author":"Cardinale","year":"2024","journal-title":"Brain Sci."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111456_bb0085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ejn.13482","article-title":"L-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?","volume":"45","author":"Carta","year":"2017","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0090","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fneur.2014.00242","article-title":"Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications","volume":"5","author":"Cenci","year":"2014","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111456_bb0095","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/mds.27337","article-title":"Animal models of l-dopa-induced dyskinesia in Parkinson\u2019s disease","volume":"33","author":"Cenci","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0100","article-title":"Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson\u2019s disease in rats and mice","volume":"9","author":"Cenci","year":"2007","journal-title":"Curr. Protocneurosci."},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111456_bb0105","first-page":"2694","article-title":"L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111456_bb0110","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0306-4522(99)00294-8","article-title":"Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment","volume":"94","author":"Cenci","year":"1999","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111456_bb0115","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/mds.27959","article-title":"Dyskinesia matters","volume":"35","author":"Cenci","year":"2020","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111456_bb0120","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.neuroscience.2006.02.074","article-title":"Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain","volume":"139","author":"Cristino","year":"2006","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111456_bb0125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12640-013-9406-3","article-title":"Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment","volume":"25","author":"Del-Bel","year":"2014","journal-title":"Neurotox. Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111456_bb0130","first-page":"168","article-title":"Nitric oxide, a new player in L-DOPA-induced dyskinesia?","volume":"7","author":"Del-Bel","year":"2015","journal-title":"Front. Biosci. (Elite Ed.)"},{"key":"10.1016\/j.pnpbp.2025.111456_bb0135","series-title":"Synapse (New York, N.Y.)","first-page":"479","article-title":"l-DOPA-induced dyskinesia in Parkinson\u2019s disease: Are neuroinflammation and astrocytes key elements?","volume":"vol. 70(12)","author":"Del-Bel","year":"2016"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111456_bb0140","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.pnpbp.2025.111456_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.617085","article-title":"Contributive role of TNF-\u03b1 to L-DOPA-induced dyskinesia in a unilateral 6-OHDA lesion model of Parkinson\u2019s disease","volume":"11","author":"Dos Santos Pereira","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111456_bb0150","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/glia.24489","article-title":"The two synthetic cannabinoid compounds 4\u2019-F-CBD and HU-910 efficiently restrain inflammatory responses of brain microglia and astrocytes","volume":"72","author":"Dos Santos Pereira","year":"2024","journal-title":"Glia"},{"key":"10.1016\/j.pnpbp.2025.111456_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.109926","article-title":"4\u2032-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: contribution of anti-inflammatory and anti-glutamatergic mechanisms","volume":"251","author":"Dos Santos Pereira","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2025.111456_bb0160","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nbd.2016.06.013","article-title":"Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: possible mechanism of action","volume":"94","author":"Dos-Santos-Pereira","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2024.110996","article-title":"Cannabidiol and it fluorinate analog PECS-101 reduces hyperalgesia and allodynia in trigeminal neuralgia via TRPV1 receptors","volume":"132","author":"Escobar-Espinal","year":"2024","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111456_bb0170","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/JEP.S265282","article-title":"Pathophysiological mechanisms and experimental pharmacotherapy for L-Dopa-induced dyskinesia","volume":"13","author":"Fabbrini","year":"2021","journal-title":"J. Exp. Pharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111456_bb0175","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2125.2012.04341.x","article-title":"Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?","volume":"75","author":"Fern\u00e1ndez-Ruiz","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111456_bb0180","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1046\/j.1460-9568.2003.02896.x","article-title":"Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias","volume":"18","author":"Ferrer","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.567222","article-title":"Neuroanatomical and microglial alterations in the striatum of levodopa-treated, Dyskinetic Hemi-Parkinsonian Rats","volume":"14","author":"Fletcher","year":"2020","journal-title":"Front. Neurosci."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111456_bb0190","first-page":"357","article-title":"Fine-tuning of defensive behaviors in the dorsal periaqueductal gray by atypical neurotransmitters. Brazilian journal of medical and biological research =","volume":"45","author":"Foga\u00e7a","year":"2012","journal-title":"Revista brasileira de pesquisas medicas e biologicas"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111456_bb0195","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00213-012-2927-2","article-title":"Effects of glutamate NMDA and TRPV1 receptor antagonists on the biphasic responses to AEA injected into the dorsolateral periaqueductal grey of Wistar rats","volume":"226","author":"Foga\u00e7a","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111456_bb0200","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neuropharm.2018.03.001","article-title":"The endocannabinoid system mediates the anxiolytic effects of cannabidiol in chronically stressed mice: role of neurogenesis and dendritic remodeling","volume":"135","author":"Foga\u00e7a","year":"2018","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111456_bb0205","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/mds.10289","article-title":"Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson\u2019s disease","volume":"17","author":"Fox","year":"2002","journal-title":"Mov. Disord."},{"issue":"13","key":"10.1016\/j.pnpbp.2025.111456_bb0210","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/bph.13215","article-title":"Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia","volume":"173","author":"Garc\u00eda","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111456_bb0215","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/0165-1838(96)00037-9","article-title":"Effect of acute cold exposure on norepinephrine turnover rates in rat white adipose tissue","volume":"60","author":"Garofalo","year":"1996","journal-title":"J. Auton. Nerv. Syst."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111456_bb0220","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1034\/j.1600-0773.2003.930202.x","article-title":"The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats","volume":"93","author":"Gilgun-Sherki","year":"2003","journal-title":"Pharmacol. Toxicol."},{"issue":"16","key":"10.1016\/j.pnpbp.2025.111456_bb0225","doi-asserted-by":"crossref","first-page":"8920","DOI":"10.3390\/ijms22168920","article-title":"Neuroprotective and symptomatic effects of Cannabidiol in an animal model of Parkinson\u2019s disease","volume":"22","author":"Giuliano","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0230","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.nbd.2013.10.008","article-title":"Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson\u2019s disease","volume":"62","author":"Gonz\u00e1lez-Aparicio","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111456_bb0235","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF02244012","article-title":"Antianxiety effect of cannabidiol in the elevated plus-maze","volume":"100","author":"Guimar\u00e3es","year":"1990","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111456_bb0240","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.220370","article-title":"7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human parkinsonian primate","volume":"13","author":"Herrero","year":"2023","journal-title":"Open Biol."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111456_bb0245","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of L-DOPA-induced dyskinesia in Parkinson\u2019s disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111456_bb0250","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","article-title":"Molecular targets of cannabidiol in neurological disorders","volume":"12","author":"Ibeas Bih","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111456_bb0255","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12640-019-00109-8","article-title":"Cannabidiol and cannabinoid compounds as potential strategies for treating Parkinson\u2019s disease and L-DOPA-induced dyskinesia","volume":"37","author":"Junior","year":"2020","journal-title":"Neurotox. Res."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111456_bb0260","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1124\/mol.105.016428","article-title":"Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity","volume":"69","author":"Kim","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0265","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neurobiolaging.2019.05.019","article-title":"Late aging-associated increases in L-DOPA-induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat","volume":"81","author":"Lanza","year":"2019","journal-title":"Neurobiol. Aging"},{"issue":"20","key":"10.1016\/j.pnpbp.2025.111456_bb0270","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"Pt 7","key":"10.1016\/j.pnpbp.2025.111456_bb0275","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/brain\/123.7.1365","article-title":"Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson\u2019s disease","volume":"123","author":"Lee","year":"2000","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111456_bb0280","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances AEA signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111456_bb0285","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","article-title":"Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test","volume":"41","author":"Linares","year":"2019","journal-title":"Brazilian J. Psychiatr."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108916","article-title":"2-Arachidonoylglycerol mobilization following brief synaptic stimulation in the dorsal lateral striatum requires glutamatergic and cholinergic neurotransmission","volume":"205","author":"Liput","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2025.111456_bb0300","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.neuropharm.2013.07.008","article-title":"Complex interaction between AEA and the nitrergic system in the dorsolateral periaqueductal gray to modulate anxiety-like behavior in rats","volume":"75","author":"Lisboa","year":"2013","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111456_bb0305","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.nbd.2004.01.007","article-title":"A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function","volume":"16","author":"Lundblad","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0310","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bbr.2014.02.039","article-title":"The effects of unilateral 6-OHDA lesion in medial forebrain bundle on the motor, cognitive dysfunctions and vulnerability of different striatal interneuron types in rats","volume":"266","author":"Ma","year":"2014","journal-title":"Behav. Brain Res."},{"issue":"36","key":"10.1016\/j.pnpbp.2025.111456_bb0315","doi-asserted-by":"crossref","first-page":"33896","DOI":"10.1074\/jbc.M303994200","article-title":"The endocannabinoid system in human keratinocytes. Evidence that AEA inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase","volume":"278","author":"Maccarrone","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0320","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fnbeh.2011.00063","article-title":"Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects","volume":"5","author":"Marco","year":"2011","journal-title":"Front. Behav. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111456_bb0325","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.neures.2011.12.006","article-title":"The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats","volume":"72","author":"Martinez","year":"2012","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0330","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.nbd.2014.11.024","article-title":"Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats","volume":"74","author":"Martinez","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111456_bb0335","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1358\/dot.2015.51.5.2313726","article-title":"Current treatment and future prospects of dopa-induced dyskinesias","volume":"51","author":"Mazzucchi","year":"2015","journal-title":"Drugs Today (Barcelona, Spain : 1998)"},{"key":"10.1016\/j.pnpbp.2025.111456_bb0340","doi-asserted-by":"crossref","unstructured":"Mechoulam, R., Peters, M., Murillo-Rodriguez, E., & Hanus, L. O. (2007). Cannabidiol--recent advances. Chem. Biodivers., 4(8), 1678\u20131692. doi: https:\/\/doi.org\/10.1002\/cbdv.200790147.","DOI":"10.1002\/cbdv.200790147"},{"issue":"1607","key":"10.1016\/j.pnpbp.2025.111456_bb0345","first-page":"3276","article-title":"Hub and switches: endocannabinoid signalling in midbrain dopamine neurons","volume":"367","author":"Melis","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111456_bb0350","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1073\/pnas.97.7.3655","article-title":"Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human","volume":"97","author":"Mezey","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111456_bb0355","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.neuron.2020.01.039","article-title":"Advanced Neurotechnologies for the restoration of motor function","volume":"105","author":"Micera","year":"2020","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111456_bb0360","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.expneurol.2007.07.021","article-title":"Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson\u2019s disease: role of CB(1) and TRPV1 receptors","volume":"208","author":"Morgese","year":"2007","journal-title":"Exp. Neurol."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111456_bb0365","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3390\/cells11040691","article-title":"Prevention of L-Dopa-induced Dyskinesias by MPEP blockade of metabotropic glutamate receptor 5 is associated with reduced inflammation in the brain of parkinsonian monkeys","volume":"11","author":"Morissette","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.pnpbp.2025.111456_bb0370","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.expneurol.2016.09.013","article-title":"Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson\u2019s disease","volume":"286","author":"Mulas","year":"2016","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111456_bb0375","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bpsgos.2021.06.014","article-title":"Cannabidiol produces distinct U-shaped dose-response effects on cocaine-induced conditioned place preference and associated recruitment of Prelimbic neurons in male rats","volume":"2","author":"Nedelescu","year":"2022","journal-title":"Biol Psychiatry Glob Open Sci"},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111456_bb0380","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/mds.28215","article-title":"Continuous dopaminergic stimulation as a treatment for Parkinson\u2019s disease: current status and future opportunities","volume":"35","author":"Olanow","year":"2020","journal-title":"Movement Dis."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0385","first-page":"1158","article-title":"A micro salting-out assisted liquid-liquid extraction combined with ultra-high performance liquid chromatography tandem mass spectrometry to determine AEA and 2-arachidonoylglycerol in rat brain samples","author":"Oliveira","year":"2020","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2020.461766","article-title":"In-tube solid-phase microextraction directly coupled to tandem mass spectrometry for AEA and 2-arachidonoylglycerol determination in rat brain samples from an animal model of Parkinson\u2019s disease","volume":"1636","author":"Oliveira","year":"2021","journal-title":"J. Chromatogr. A"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111456_bb0395","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/jnnp.2007.129015","article-title":"Punding in Parkinson\u2019s disease","volume":"7","author":"O\u2019Sullivan","year":"2007","journal-title":"Pract. Neurol."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111456_bb0400","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.neuroscience.2009.01.034","article-title":"Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson\u2019s disease","volume":"159","author":"Padovan-Neto","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2025.111456_bb0405","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fnsys.2011.00040","article-title":"Nitric oxide synthase inhibitor improves De novo and long-term l-DOPA-induced dyskinesia in Hemiparkinsonian rats","volume":"5","author":"Padovan-Neto","year":"2011","journal-title":"Front. Syst. Neurosci."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0410","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neuropharm.2014.08.019","article-title":"Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats","volume":"89","author":"Padovan-Neto","year":"2015","journal-title":"Neuropharmacology"},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2025.111456_bb0415","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2011.01.013","article-title":"Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum","volume":"655","author":"Pandolfo","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0420","series-title":"The Rat Brain in Stereotaxic Coordinates - the NewCoronal Set","author":"Paxinos","year":"2004"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111456_bb0425","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108693","article-title":"Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT1A\/1B receptor agonist and A2A receptor antagonist","volume":"196","author":"Pinna","year":"2021","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111456_bb0435","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00702-018-1874-4","article-title":"Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function","volume":"125","author":"Pisanu","year":"2018","journal-title":"Journal of neural transmission (Vienna, Austria\u202f: 1996)"},{"issue":"11","key":"10.1016\/j.pnpbp.2025.111456_bb0440","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/mds.20988","article-title":"Development of dyskinesias in a 5-year trial of ropinirole and L-dopa","volume":"21","author":"Rascol","year":"2006","journal-title":"Movement Dis."},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111456_bb0445","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/ejn.16259","article-title":"Sodium nitroprusside enhances stepping test performance and increases medium spiny neurons responsiveness to cortical inputs in a rat model of levodopa-induced dyskinesias","volume":"59","author":"Ribeiro","year":"2024","journal-title":"Eur. J. Neurosci."},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111456_bb0450","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1517\/14740338.2011.575778","article-title":"Abuse potential and psychoactive effects of \u03b4-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine","volume":"10","author":"Robson","year":"2011","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0455","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.nbd.2018.06.019","article-title":"The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing\/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia","volume":"118","author":"Rojo-Bustamante","year":"2018","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111456_bb0460","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.biopsych.2014.03.023","article-title":"Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice","volume":"77","author":"Ruiz-DeDiego","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111456_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106278","article-title":"D2 dopamine receptors and the striatopallidal pathway modulate L-DOPA-induced dyskinesia in the mouse","volume":"186","author":"S\u00e1ez","year":"2023","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111456_bb0470","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12035-007-0004-3","article-title":"Cannabinoids and neuroprotection in basal ganglia disorders","volume":"36","author":"Sagredo","year":"2007","journal-title":"Mol. Neurobiol."},{"issue":"26","key":"10.1016\/j.pnpbp.2025.111456_bb0475","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1523\/JNEUROSCI.0852-07.2007","article-title":"Critical involvement of cAMP\/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia","volume":"27","author":"Santini","year":"2007","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111456_bb0480","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00702-021-02447-4","article-title":"Levodopa-induced dyskinesias in Parkinson\u2019s disease increase cerebrospinal fluid nitric oxide metabolites\u2019 levels","volume":"129","author":"Santos-Lobato","year":"2022","journal-title":"J. Neural Transm. (Vienna, Austria\u202f: 1996)"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111456_bb0485","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41531-024-00836-6","article-title":"Molecular and cellular determinants of L-Dopa-induced dyskinesia in Parkinson\u2019s disease","volume":"10","author":"Servillo","year":"2024","journal-title":"NPJ Parkinson\u2019s disease"},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111456_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203135","article-title":"Selective ablation of striatal striosomes produces the deregulation of dopamine nigrostriatal pathway","volume":"13","author":"Shumilov","year":"2018","journal-title":"PLoS One"},{"issue":"Pt B","key":"10.1016\/j.pnpbp.2025.111456_bb0495","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.pnpbp.2017.07.012","article-title":"Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative","volume":"79","author":"Silva","year":"2017","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111456_bb0500","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s13311-021-01164-w","article-title":"The Cannabidiol analog PECS-101 prevents chemotherapy-induced neuropathic pain via PPAR\u03b3 receptors","volume":"19","author":"Silva","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pnpbp.2025.111456_bb0505","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.nbd.2014.09.010","article-title":"Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(\u2212\/\u2212) aphakia mice","volume":"73","author":"Sol\u00eds","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111456_bb0510","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/0306-4522(82)90035-5","article-title":"A note on the use of picric acid-paraformaldehyde-glutaraldehyde fixative for correlated light and electron microscopic immunocytochemistry","volume":"7","author":"Somogyi","year":"1982","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2025.111456_bb0515","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bbi.2018.09.014","article-title":"Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPAR\u03b3 receptors","volume":"74","author":"Sonego","year":"2018","journal-title":"Brain Behav. Immun."},{"issue":"50","key":"10.1016\/j.pnpbp.2025.111456_bb0520","doi-asserted-by":"crossref","first-page":"13739","DOI":"10.1523\/JNEUROSCI.3258-07.2007","article-title":"Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways","volume":"27","author":"Starowicz","year":"2007","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111456_bb0525","doi-asserted-by":"crossref","first-page":"456","DOI":"10.7326\/0003-4819-83-4-456","article-title":"Five years\u2019 treatment of Parkinson\u2019s disease with levodopa. Therapeutic results and survival of 100 patients","volume":"83","author":"Sweet","year":"1975","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pnpbp.2025.111456_bb0530","doi-asserted-by":"crossref","unstructured":"Takuma K, Tanaka T, Takahashi T, Hiramatsu N, Ota Y, Ago Y, Matsuda T (2012) Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-parkinsonian rats. Eur. J. Pharmacol. 683(1\u20133):166\u2013173. doi:https:\/\/doi.org\/10.1016\/j.ejphar.2012.03.008.","DOI":"10.1016\/j.ejphar.2012.03.008"},{"key":"10.1016\/j.pnpbp.2025.111456_bb0540","first-page":"3234","article-title":"Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson\u2019s disease","volume":"60","author":"Thiele","year":"2012","journal-title":"J. Visualiz. Exp.\u202f: JoVE"},{"issue":"24","key":"10.1016\/j.pnpbp.2025.111456_bb0545","doi-asserted-by":"crossref","first-page":"e2238","DOI":"10.1212\/WNL.0000000000006643","article-title":"Levodopa-induced dyskinesia in Parkinson disease: A population-based cohort study","volume":"91","author":"Turcano","year":"2018","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111456_bb0550","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.387","article-title":"The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG","volume":"4","author":"Valdeolivas","year":"2013","journal-title":"Cell Death Dis."},{"issue":"9","key":"10.1016\/j.pnpbp.2025.111456_bb0555","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1096\/fj.04-3010fje","article-title":"A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson\u2019s disease","volume":"19","author":"van der Stelt","year":"2005","journal-title":"FASEB J."},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111456_bb0560","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","article-title":"Progress towards therapies for disease modification in Parkinson\u2019s disease","volume":"20","author":"Vijiaratnam","year":"2021","journal-title":"Lancet. Neurol."},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111456_bb0565","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.tins.2004.06.006","article-title":"Putting a spin on the dorsal-ventral divide of the striatum","volume":"27","author":"Voorn","year":"2004","journal-title":"Trends Neurosci."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111456_bb0570","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1152\/jn.01023.2006","article-title":"TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons","volume":"97","author":"Xing","year":"2007","journal-title":"J. Neurophysiol."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111456_bb0575","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jneumeth.2004.10.004","article-title":"Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson\u2019s disease","volume":"144","author":"Yuan","year":"2005","journal-title":"J. Neurosci. Methods"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111456_bb0580","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016116","article-title":"Capsaicin-induced changes in LTP in the lateral amygdala are mediated by TRPV1","volume":"6","author":"Zschenderlein","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2025.111456_bb0585","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fphar.2017.00259","article-title":"Inverted U-shaped dose-response curve of the anxiolytic effect of Cannabidiol during public speaking in Real life","volume":"8","author":"Zuardi","year":"2017","journal-title":"Front. Pharmacol."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584625002106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584625002106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T19:32:49Z","timestamp":1765913569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584625002106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":115,"alternative-id":["S0278584625002106"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111456","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111456"}}